1. Home
  2. IFRX vs NDLS Comparison

IFRX vs NDLS Comparison

Compare IFRX & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.11

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$12.53

Market Cap

68.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFRX
NDLS
Founded
2007
1995
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
66.0M
68.7M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
IFRX
NDLS
Price
$2.11
$12.53
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$6.25
N/A
AVG Volume (30 Days)
1.4M
48.0K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$495,089,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.37
52 Week Low
$0.71
$0.47
52 Week High
$2.20
$12.75

Technical Indicators

Market Signals
Indicator
IFRX
NDLS
Relative Strength Index (RSI) 81.36 81.80
Support Level $0.86 $0.62
Resistance Level N/A N/A
Average True Range (ATR) 0.22 0.78
MACD 0.07 0.24
Stochastic Oscillator 90.31 91.32

Price Performance

Historical Comparison
IFRX
NDLS

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

Share on Social Networks: